Related Articles
Efficacy and safety of second‑generation CAR T‑cell therapy in diffuse large B‑cell lymphoma: A meta‑analysis
Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor
CAR‑T 19 combined with reduced‑dose PD‑1 blockade therapy for treatment of refractory follicular lymphoma: A case report
Dual specific CD19/CD22‑targeted chimeric antigen receptor T‑cell therapy for refractory diffuse large B‑cell lymphoma: A case report
CAR T cell therapy: A new era for cancer treatment (Review)